OP0069 FACTORS ASSOCIATED WITH THE RISK OF SEPSIS IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATED WITH ANTI-TUMOR NECROSIS FACTOR-ALPHA: A NATIONWIDE, POPULATION-BASED COHORT STUDY

Background: Anti-TNF-α agents have been proven to be effective for patients with immune-medicated inflammatory diseases (IMIDs) including rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriasis (PsO), psoriatic arthritis (PsA), Crohn’s disease (CD) and ulcerative colitis (UC). Prior studies have shown an increased risk of infection in IMID patients treated with anti-TNF-α but limited studies investigated factors associated with the development of sepsis in patients with IMIDs. Objectives: To investigate factors associated with the development of sepsis in patients with IMIDs using the Taiwanese National Health Insurance Research Database (NHIRD). Methods: We identified all biologic-naïve patients with RA, AS, PsO, PsA, or CD/UC from the claim data via the NHIRD who started their first anti-TNF-α agent (etanercept (ETN), adalimumab (ADA) or golimumab (GOL)) between 2003 and 2017 as study subjects. The index date was the first date of anti-TNF-α prescription. Sepsis was defined based on the sepsis-3 definition. We identified sepsis patients using a validated ICD-9-CM coding system proposed by Angus et al, in which a diagnosis of bacterial/fungal infection with one or more acute organ dysfunction is required to define an episode of sepsis. All study subjects were followed up till the date of first hospitalization due to sepsis, 90 days after the last date of anti-TNF-α prescription, withdrawal from NHIRD or death, whichever came first. We used a Cox regression analysis to assess the associations of covariates with the risk of sepsis shown as hazard ratios (HRs) with 95% confidence interval (CIs). Covariates included anti-TNF-α agent, IMID, age, sex, insured amount, level of urbanization, disease duration, Charlson comorbidity index (CCI), a history of prior hospitalization due to sepsis within 3 months before the index date and medication use within 12 months before the index date and during the follow-up period. Results: We identified 18105 biologic-naïve patients with IMIDs, including 8123 ETN users, ...